Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.52 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.47 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.44 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.43 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.42 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.40 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1060872 | 1.00 | CHKA (0.57) | CHKAADRB2NCF1PLD1ROCK2 | |
| Hydrochloric Acid SCHEMBL7328290 | 0.98 | CHKA (0.55) | CHKAADRB2NCF1PLD1ROCK2 | |
| SCHEMBL223203 | 0.98 | CHKA (0.59) | CHKAADRB2NCF1PLD1ROCK2 | |
| SCHEMBL14275562 | 0.86 | CHKA (0.50) | CHKAADRB2NCF1PLD1ROCK2 | |
| Trifluoroacetic Acid SCHEMBL1456945 | 0.82 | DPP4 (0.59) | CHKAHRH3DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL8879338 | 0.80 | CHKA (0.57) | CHKAADRB2NCF1PLD1HRH3 | |
| Hydrochloric Acid SCHEMBL16684779 | 0.79 | HRH3 (0.42) | CHKAROCK2ROCK1HRH3TSHR | |
| Hydrochloric Acid SCHEMBL785566 | 0.79 | CHKA (0.52) | CHKAADRB2NCF1PLD1ROCK2 | |
| SCHEMBL4711666 | 0.79 | CHKA (0.61) | CHKAADRB2NCF1PLD1HRH3 | |
| Hydrochloric Acid SCHEMBL17927700 | 0.79 | MBTD1 (0.55) | DPP4TSHRCYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169575-B1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMA (JP) | 2026-01-07 | — | — | EP | disclosed |
| CN-115667259-B | Fused ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2025-06-17 | — | — | CN | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2857388-A1 | Azoles containing sulfone | Grünenthal GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| WO-2010089084-A1 | SUBSTITUTED INDOLE COMPOUNDS AS BRADYKININ RECEPTOR 1 MODULATORS | Grünenthal GmbH (DE) | 2010-08-12 | — | — | WO | disclosed |
| EP-2021316-A1 | INHIBITORS OF POLO-LIKE KINASES | Abbott Laboratories (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBVIE INC. | 2008-01-17 | — | — | US | disclosed |
| US-7317027-B2 | 1-substituted 2-carboxamide derivatives of fused ring pyrroles, especially pyrrolo[2,3-b]pyridines and pyrrolo[3,2-b]pyridines, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| WO-2007140233-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1636226-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | F12, F5, F11 | ADRB2 1331/4885ROCK2 193/4885ROCK1 215/4885 |
| US-20100222324-A1 | Substituted Indole Compounds | BDKRB1, BDKRB2, EDNRB | ADRB2 45/4885ROCK2 1906/4885ROCK1 599/4885 |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | F12, F5, F11 | ADRB2 1241/4885ROCK2 119/4885ROCK1 133/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | ADRB2 1825/4885ROCK2 1724/4885ROCK1 948/4885 |
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | PLK1, PLK2, BUB1B | ADRB2 4716/4885ROCK2 644/4885ROCK1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.